API
< Back to all clusters
[HEALTH] · Brazil · 15 sources

started · updated

Anvisa approves five new GLP-1 medications for diabetes and obesity

Brazil's National Health Surveillance Agency (Anvisa) has approved the registration of five new GLP-1 receptor agonist injectable medications, commonly referred to as ‘weight-loss pens’. This brings the total number of approvals for this class of drugs in 2026 to 20.

The new medications include three indicated for type 2 diabetes and two for obesity management. The approved products are Aribet, Lyrza, and Wylovol (all containing liraglutide), as well as Embeltah and Sevema (both containing semaglutide). Manufacturers include Biocon, OneSource Specialty, Farma Vision, Dr. Reddy’s, and Aché Laboratórios.

This regulatory expansion follows a request from the Ministry of Health to strengthen the national market supply and improve access through the Unified Health System (SUS). While the approvals aim to increase competition and availability, medical specialists have noted that high costs remain a significant barrier to access in both public and private healthcare sectors in Brazil.

Entities

Anvisa · Biocon · Brazil · Bruno Geloneze · Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · Marcio Mancini · Ministry of Health · National Health Service · OneSource Specialty · Portugal · UMG-Associação de Utentes de Medicamentos Genéricos · Unicamp

Claims

What the coverage asserts, and how many sources carry each claim.

Sources